BRWA
AKBA icon

B. Riley Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

B. Riley Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,360
Closed -$82.4K – 1323
2024
Q4 		$82.4K Hold
43,360
– – ﹤0.01% 1112
2024
Q3 		$57.2K Hold
43,360
– – ﹤0.01% 1234
2024
Q2 		$44.2K Buy
+43,360
New +$53.6K ﹤0.01% 1349
2023
Q2 		– Sell
-13,000
Closed -$7.29K – 1540
2023
Q1 		$7.29K Buy
+13,000
New +$9.93K ﹤0.01% 1499

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

B. Riley Wealth Advisors's AKBA Position: Q1 2025 in Review

B. Riley Wealth Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2025, closing a stake of 43,360 shares — an estimated $82.4K sold.

B. Riley Wealth Advisors first reported a position in AKBA in Q1 2023 and held it in 4 quarters. The position peaked at $82.4K in Q4 2024. 143 funds tracked by Wall St. Rank hold AKBA as of Q1 2025.

  • B. Riley Wealth Advisors reported no remaining Akebia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 43,360 Akebia Therapeutics shares in Q1 2025, an estimated $82.4K.
  • B. Riley Wealth Advisors first reported a position in Akebia Therapeutics in Q1 2023 and held it in 4 quarters.
  • B. Riley Wealth Advisors's Akebia Therapeutics position peaked at $82.4K in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2025.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2025, filed 28 Aug 2026.